Prevalence of Long COVID-associated symptoms in adults with and without SARS-CoV-2 infection in Germany: Results of the population-based study: Corona Monitoring Nationwide 2021/22 (RKI-SOEP-2)

Background Controlled population-based studies on long-term health sequelae of SARS-CoV-2 can help to identify clinical signs specific to Long COVID and to evaluate this emerging public health challenge. Aim To examine prevalence differences of Long COVID-associated symptoms among adults with and without SARS-CoV-2 infection in Germany. Methods This population-based, retrospective study (11/2021-2/2022) included 7,683 working aged adults (18-65 years), a subset of the Corona Monitoring Nationwide study in Germany. Prior SARS-CoV-2 infection was defined based on self-reported PCR-confirmed infections and IgG-antibody dried blood spot testing. Participants answered a questionnaire including 19 common symptoms of Long COVID experienced in the six months preceding the survey. We estimated population-weighted prevalence of (1) individual symptoms, and (2) [≥]1 symptom, with and without impact on work ability, by infection status within strata of sex, age group, income and comorbidity. We calculated model-adjusted prevalence differences and the probability that symptoms among infected are attributable to infection. Results 12 of 19 symptoms showed a significantly higher prevalence in infected than non-infected participants, including fatigue (27.5% versus 18.3%; p<0.001), concentration problems (22.2% vs. 13.1%; p<0.001), shortness of breath (15.6% vs. 7.5%; p<0.001), and smell and taste disorder (10% vs. 1.2%; p<0.001). [≥]1 symptom with impact on work ability was more prevalent following infection (16.0% vs. 12.2%; p=0.06) with a model-adjusted prevalence difference of 3.8% (95%-CI -0.5-8.0). Conclusion We observed a rather small excess prevalence attributable to SARS-CoV-2 infection. However, the absolute number of persons places great demands on the health care system and may affect economic productivity.

[1]  B. Gaertner,et al.  Long-term health consequences among individuals with SARS-CoV-2 infection compared to individuals without infection: results of the population-based cohort study CoMoLo Follow-up , 2023, BMC Public Health.

[2]  M. Puhan,et al.  Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study , 2023, BMJ.

[3]  S. Flottorp,et al.  Prevalence of long COVID complaints in persons with and without COVID-19 , 2023, Scientific reports.

[4]  T. Henrich,et al.  Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC) , 2023, eLife.

[5]  Sudip Bhattacharya,et al.  Pooled Prevalence of Long COVID-19 Symptoms at 12 Months and Above Follow-Up Period: A Systematic Review and Meta-Analysis. , 2023, Cureus.

[6]  E. Topol,et al.  Long COVID: major findings, mechanisms and recommendations , 2023, Nature Reviews Microbiology.

[7]  A. Qureshi,et al.  COVID-Specific Long-term Sequelae in Comparison to Common Viral Respiratory Infections: An Analysis of 17 487 Infected Adult Patients , 2022, Open forum infectious diseases.

[8]  K. Khunti,et al.  The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis , 2022, eClinicalMedicine.

[9]  U. Behrends,et al.  Post‐COVID‐19 condition in the German working population: A cross‐sectional study of 200,000 registered stem cell donors , 2022, Journal of internal medicine.

[10]  L. Wieler,et al.  Post-COVID-19-associated morbidity in children, adolescents, and adults: A matched cohort study including more than 157,000 individuals with COVID-19 in Germany , 2022, PLoS medicine.

[11]  J. Steinacker,et al.  Post-acute sequelae of covid-19 six to 12 months after infection: population based study , 2022, BMJ.

[12]  Jill P. Pell,et al.  Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study , 2022, Nature Communications.

[13]  Christopher J. L. Murray,et al.  Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. , 2022, JAMA.

[14]  A. Schaffrath Rosario,et al.  Corona Monitoring Nationwide (RKI-SOEP-2): Seroepidemiological Study on the Spread of SARS-CoV-2 Across Germany , 2022, Jahrbücher für Nationalökonomie und Statistik.

[15]  J. Rosmalen,et al.  Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study , 2022, The Lancet.

[16]  C. Scheidt-Nave,et al.  Long-Term Health Symptoms and Sequelae Following SARS-CoV-2 Infection: An Evidence Map , 2022, International journal of environmental research and public health.

[17]  F. Carrat,et al.  Kinetics of anti-nucleocapsid IgG response in COVID-19 immunocompetent convalescent patients , 2022, Scientific Reports.

[18]  Heidi Ledford How common is long COVID? Why studies give different answers , 2022, Nature.

[19]  Janet Diaz,et al.  A clinical case definition of post-COVID-19 condition by a Delphi consensus , 2021, The Lancet Infectious Diseases.

[20]  S. Rosenkranz,et al.  Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study , 2021, The Lancet Regional Health - Europe.

[21]  U. Heininger,et al.  Beschluss und Wissenschaftliche Begründung der Ständigen Impfkommission (STIKO) für die COVID-19-Impfempfehlung , 2020 .

[22]  F. Callard,et al.  How and why patients made Long Covid , 2020, Social Science & Medicine.

[23]  R. Trimble COVID-19 Dashboard , 2020 .

[24]  R. Newson REGPAR: Stata module to compute population attributable risks from binary regression models , 2015 .

[25]  R. Evans European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).